Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 10/20 | 0.80 |
| ▸ | CDK9 | P50750 | 7/20 | 0.80 |
| ▸ | CDK7 | P50613 | 7/20 | 0.80 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.80 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.80 |
| ▸ | CDK1 | P06493 | 5/20 | 0.80 |
| ▸ | CDK12 | Q9NYV4 | 5/20 | 0.80 |
| ▸ | CCNK | O75909 | 4/20 | 0.80 |
| ▸ | GSK3B | P49841 | 3/20 | 0.80 |
| ▸ | CCNH | P51946 | 3/20 | 0.80 |
| ▸ | MNAT1 | P51948 | 3/20 | 0.80 |
| ▸ | GSK3A | P49840 | 2/20 | 0.80 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.80 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.80 |
| ▸ | CDK13 | Q14004 | 2/20 | 0.80 |
| ▸ | CCNT2 | O60583 | 1/20 | 0.80 |
| ▸ | BRD4 | O60885 | 1/20 | 0.80 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.80 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.80 |
| ▸ | CDK4 | P11802 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30356828 | 0.92 | CDK2 (0.74) | CDK2CDK9CDK7CCNE1CDK5 | |
| SCHEMBL12953706 | 0.92 | CDK2 (0.75) | CDK2CDK9CDK7CCNE1CDK5 | |
| SCHEMBL16198015 | 0.92 | CDK2 (0.75) | CDK2CDK9CDK7CCNE1CDK5 | |
| SCHEMBL23815646 | 0.91 | CDK2 (0.84) | CDK2CDK9CDK7CCNE1CDK5 | |
| SCHEMBL20366942 | 0.91 | CDK2 (0.84) | CDK2CDK9CDK7CCNE1CDK5 | |
| SCHEMBL18122698 | 0.91 | CDK2 (0.74) | CDK2CDK9CDK7CCNE1CDK5 | |
| SCHEMBL20549653 | 0.91 | CDK2 (0.74) | CDK2CDK9CDK7CCNE1CDK5 | |
| SCHEMBL18122688 | 0.91 | CDK2 (0.74) | CDK2CDK9CDK7CCNE1CDK5 | |
| SCHEMBL15576865 | 0.90 | CDK2 (0.86) | CDK2CDK9CDK7CCNE1CDK5 | |
| SCHEMBL30356835 | 0.90 | CDK2 (0.69) | CDK2CDK9CDK7CCNE1CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160193334-A1 | TREATING CANCER WITH A COMBINATION OF A PD-1 ANTAGONIST AND DINACICLIB | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193334-A1 | TREATING CANCER WITH A COMBINATION OF A PD-1 ANTAGONIST AND DINACICLIB | PDCD1, CD274, PDCD1LG2 | CDK2 16/4885CDK9 14/4885CDK7 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.